Dated: July 1, 2003.

Edward Schultz,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 03–17173 Filed 7–7–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 03112]

Enhancement of Antenatal Care Services and Blood Safety for Preventing Transmission of HIV, Syphilis, and Malaria in the Republic of Tanzania; Notice of Intent To Fund Single Eligibility Award

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2003 funds for a cooperative agreement program in the Republic of Tanzania for (1) the enhancement of antenatal care (ANC) services with emphasis on prevention of mother to child transmission (PMTCT) of HIV; and (2) the enhancement of blood safety with emphasis on preventing transmission of HIV, syphilis, and malaria. The Catalog of Federal Domestic Assistance number for this program is 93.941.

B. Eligible Applicants

Assistance will be provided only to the Department of Diagnostic Services (DDS) of the Ministry of Health (MOH) in Tanzania. No other applications are solicited.

The DDS is currently the only appropriate and qualified organization to conduct a specific set of activities supportive of the CDC Global AIDS Program's (GAP) goals for enhancing ANC services and blood safety in Tanzania for the following reasons:

1. The DDS is uniquely positioned, in terms of legal authority, ability, and credibility among Tanzanian citizens, to coordinate the implementation of national initiatives for PMTCT and blood safety.

2. The DDS has developed national PMTCT and blood safety guidelines, and strategic plans for enhancing PMTCT services and blood safety in Tanzania, which allows the DDS to immediately become engaged in the activities listed in this announcement.

3. The purpose of the announcement is to build upon the existing framework of health policy and programming that the MOH itself has initiated.

4. The MOH in Tanzania has been mandated by the Tanzanian constitution to coordinate and implement activities necessary for the control of epidemics, including HIV/AIDS and STDs.

C. Funding

Approximately $1,000,000 is available in FY 2003 to fund this award; $500,000 for enhancing ANC services, and $500,000 for blood safety. It is expected that the award will begin on or about September 1, 2003, and will be made for a 12-month budget period within a project period of up to five years. Approximately $1,000,000 will be available for years two through five of the project. Funding estimates may change.

D. Where To Obtain Additional Information

For general questions or comments about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700.

For program technical assistance, contact: Eddas M. Bennett, Deputy Director, CDC Tanzania AIDS Program, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 686 Old Bagamoyo Road, Dar es Salaam, Tanzania, Telephone: 255 222 667 8001 x4819, e-mail: *ebennett@tancdc.co.tz*.

Dated: June 1, 2003.

Sandra Manning,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 03–17174 Filed 7–7–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Collection of Specimen Panels for Validation for Incidence Assays, Contract Solicitation Number 2003–N–00872

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Collection of Specimen Panels for Validation for Incidence Assays, Contract Solicitation Number 2003-N–00872.

Times and Dates: 7 p.m.–8 p.m., July 24, 2003 (Open); 8 a.m.–8:30 a.m., July 25, 2003 (Open); 8:30 a.m.–5 p.m., July 25, 2003 (Closed).

Place: The Westin Atlanta North at Perimeter Center, 7 Concourse Parkway, Atlanta, GA 30328, Telephone 770.395.3900.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Contract Solicitation Number 2003–N–00872.

For Further Information Contact: Esther Sumartojo, Ph.D., Deputy Associate Director for Science, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road, NE., MS–E07, Atlanta, GA 30333, Telephone 404.639.8006.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 27, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 03–17172 Filed 7–7–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 03N–0191]

Agency Emergency Processing Under OMB Review; Submission of Validation Data for Reprocessed Single-Use Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for emergency processing under the Paperwork Reduction Act of 1995 (the PRA). The proposed collection of information will be used by FDA to determine whether reprocessed single-use devices (SUDs) are substantially equivalent to legally marketed predicate devices. FDA is requesting this emergency processing under the PRA to implement the statutory provision under section 302 of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA).

DATES: Submit comments on the collection of information by August 7,